Methsuximide

Mesuximide

Mesuximide

Chemical compound

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]

Quick Facts Clinical data, Trade names ...

Medical use

is indicated for the control of absence seizures that are refractory to other drugs.[2]

References

  1. [1]
    Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.
  2. [2]
    Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
  3. [3]
    Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ (November 1979). "Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy". Neurology. 29 (11): 1509–13. doi:10.1212/wnl.29.11.1509. PMID 116142. S2CID 43643797.
Stub icon

This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Methsuximide, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.